Prevalence of Controlled Attenuation Parameter (CAP)-Assessed Hepatic Steatosis as a Possible Indicator of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Risk in Healthy Medical Students: A Cohort Study From South India

The findings of this study show that hepatic steatosis is prevalent even among young, evidently healthy adults. CAP measurement using FibroScan cannot substitute for a full MAFLD diagnosis without metabolic criteria; however, it can be an effective, non-invasive tool for early detection of hepatic steatosis and may have utility in screening asymptomatic populations.